During the recent session, TRACON Pharmaceuticals Inc (NASDAQ:TCON)’s traded shares were 0.79 million, with the beta value of the company hitting 1.11. At the last check today, the stock’s price was $0.25, reflecting an intraday loss of -4.73% or -$0.01. The 52-week high for the TCON share is $2.14, that puts it down -756.0 from that peak though still a striking 48.0% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $11.37M, and the average intraday trading volume over the past 10 days was 5.67 million shares, and the average trade volume was 3.36 million shares over the past three months.
TRACON Pharmaceuticals Inc (NASDAQ:TCON) trade information
TRACON Pharmaceuticals Inc (TCON) registered a -4.73% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.73% in intraday trading to $0.25, hitting a weekly high. The stock’s 5-day price performance is -41.86%, and it has moved by 26.85% in 30 days. Based on these gigs, the overall price performance for the year is -87.05%. The short interest in TRACON Pharmaceuticals Inc (NASDAQ:TCON) is 1.9 million shares and it means that shorts have 0.38 day(s) to cover.
TRACON Pharmaceuticals Inc (TCON) estimates and forecasts
Statistics show that TRACON Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. TRACON Pharmaceuticals Inc (TCON) shares have gone up 64.41% during the last six months, with a year-to-date growth rate less than the industry average at -81.82% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 83.30% this quarter and then jump 75.00% in the quarter after that. An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 61.51%. While earnings are projected to return -115.15% in 2024.
TCON Dividends
TRACON Pharmaceuticals Inc is due to release its next quarterly earnings between May 08 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TRACON Pharmaceuticals Inc (NASDAQ:TCON)’s Major holders
TRACON Pharmaceuticals Inc insiders own 2.59% of total outstanding shares while institutional holders control 11.87%, with the float percentage being 12.19%. Opaleye Management Inc. is the largest shareholder of the company, while 29 institutions own stock in it. As of Jun 29, 2023, the company held over 4.76 million shares (or 15.52% of all shares), a total value of $1.39 million in shares.
The next largest institutional holding, with 2.77 million shares, is of Ikarian Capital, LLC’s that is approximately 9.01% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $0.8 million.
Also, the Mutual Funds coming in first place with the largest holdings of TRACON Pharmaceuticals Inc (TCON) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.48 million shares. This amounts to just over 1.56 percent of the company’s overall shares, with a $0.14 million market value. The same data shows that the other fund manager holds slightly less at 0.26 million, or about 0.86% of the stock, which is worth about $76466.0.
